ChinaDrugStatus

Tofersen

托夫生
Brand: Qalsody / 凯盛迪·Neurology / Rare Disease·Last verified 2026-11-20

SOD1 antisense oligonucleotide newly added to the 2026 Commercial Health Insurance Innovative Drug List (#25) for adult SOD1-mutated ALS.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Not Listed

Not included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).

Commercial Insurance List

Announced · Effective Jan 1, 2027
2026 List Entry
#25 · 凯盛迪
Validity Period
2027-01-01 to 2028-12-31
MAH / Authorized Entity
Biogen MA Inc. · 渤健生物科技(上海)有限公司
Listed Indication Scope
Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2027-01-01)Commercial List· Catalog published: Nov 14, 2026

    2026 Commercial List · Newly Added (#25)

    Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

    Chinese original: 本品用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者。

    NHSA · PDF p.4Verified 2026-11-20

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

托夫生注射液dosage name(NHSA)
Qalsodybrand en(WHO)
凯盛迪brand zh(NHSA)

Primary Sources for This Record